Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine
- 1 December 1987
- journal article
- case report
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 65 (24) , 1164-1168
- https://doi.org/10.1007/bf01733250
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Drug interaction between propafenone and metoprolol.British Journal of Clinical Pharmacology, 1987
- Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.Circulation, 1987
- The Polymorphic Oxidation of ??-Adrenoceptor AntagonistsClinical Pharmacokinetics, 1986
- The genetic polymorphism of sparteine metabolismXenobiotica, 1986
- High-performance liquid chromatographic determination of diltiazem and four of its metabolites in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1985
- Pharmokinetics of Metoprolol in Relation to Polymorphic Sparteine OxidationPublished by Springer Nature ,1985
- Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthineEuropean Journal of Clinical Pharmacology, 1983
- Pharmacokinetics of diltiazem in selected animal species and human beingsThe American Journal of Cardiology, 1982
- Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and ResponseNew England Journal of Medicine, 1982
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979